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Abstract: Imaging of clinically relevant preclinical animal models is critical to the development of
personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived
xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant
preclinical models, their use in therapeutic development is limited by the lack of appropriate
imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled
monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging
modality for visualization of orthotopic endometrial carcinoma PDX. Application of this near-infrared
probe (EpCAM-AF680) enabled both spatio-temporal visualization of development and longitudinal
therapy monitoring of orthotopic PDX. Notably, EpCAM-AF680 facilitated imaging of multiple
PDX models representing different subtypes of the disease. Thus, the combined implementation
of EpCAM-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform for
identification and validation of new targeted therapies and corresponding response predicting
markers for endometrial carcinoma.
Keywords: endometrial carcinoma; epithelial cell adhesion molecule; near-infrared fluorescent
imaging; patient-derived xenografts; orthotopic mouse model
1. Introduction
Endometrial carcinoma is a malignancy originating in the uterine mucosa, and is currently the 6th
most common cancer in females worldwide [1]. Estimates suggest that there were close to 400,000
new cases of endometrial carcinoma resulting in approximately 90,000 deaths globally in 2018 [1].
Hysterectomy with bilateral salpingo-oophorectomy, with or without lymphadenectomy, is the primary
treatment for endometrial carcinoma. In total, 15–20% of patients will experience recurrence [2,3],
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which carries a poor prognosis (3 year survival of 8% and 14% for pelvic and distant recurrence,
respectively [4]). These patients, and patients that present with advanced disease at time of diagnosis,
usually receive adjuvant chemotherapy. However, response rates are modest with limited survival
benefit [5]. With rising incidence of endometrial carcinoma in North America and Europe (up to 19
cases per 100,000), there is a critical unmet need to develop novel therapeutics for the anticipated
increase in number of recurrent patients [6].
There are currently few targeted therapies available for the treatment of recurrent endometrial
cancer patients, e.g., pembrolizumab for endometrial tumors with a high degree of microsatellite
instability [7,8]. It is clear that further delineation of key molecular characteristics including
histologic type (low and high grade endometrioid or non-endometrioid tumors), biomarker expression
(i.e., estrogen and progesterone receptor status), and genomic classification (polymerase ε ultramutated
(POLE), microsatellite instability hypermutated, copy number high and copy number low tumors [9])
will be critical to improve the probability of beneficial outcomes in the personalized care of these
patients [2]. Thus, the development and application of clinically relevant models of endometrial
carcinoma, which accurately reflect these key clinical characteristics, will be crucial to translational
development of personalized therapies. Until recently, clinically relevant preclinical models have been
lacking for endometrial carcinoma, thus limiting the relevance of translational studies. While both
human cell line derived xenografts, and genetically engineered models (GEM) have been employed to
study response to several new drugs in vivo [10–14], they fail to reproduce the complexity, heterogeneity
and growth rates of primary clinical tumors [15]. In contrast, patient-derived xenograft (PDX)
models maintain the tissue architecture, cellular composition and molecular characteristics of tumors
from their respective donor patients [15]. Thus, PDX models are not only anticipated to capture
both the intra- and inter-tumor heterogeneity of endometrial carcinoma, as has been previously
demonstrated for breast, lung and pancreatic cancer, but also to faithfully reproduce clinical responses
to chemotherapy [16,17]. Critically, orthotopic PDX models, i.e., where primary biopsies are implanted
into the organ/microenvironment of origin, are proposed as a superior paradigm of clinical disease
compared with subcutaneous PDX [18–20]. However, a major caveat of the orthotopic approach,
particularly with patient-derived material, is longitudinal and spatio-temporal monitoring of not only
disease development and characterization but also for further intervention studies.
Despite large variations in clinical practice between hospitals, in vivo imaging (including
modalities such as transvaginal ultrasound, magnetic resonance imaging (MRI) and computed
tomography (CT) with or without positron emission tomography (PET)) play a vital role in both
the diagnosis and preoperative risk stratification of endometrial carcinoma patients [21]. Similarly,
optical imaging, typically employing bioluminescent reporter genes, have been commonly applied for
sensitive, high-throughput imaging of cell line-based xenografts [18,22]. While the use of bioluminescent
imaging (BLI) in the development and application of uterine PDXs appears attractive, particularly in
comparison to expensive and time-consuming MRI and PET/CT [18], there are caveats. Transduction of
bioluminescent reporter genes into primary patient material carries the risk of disrupting the genomic
landscape of the selected material. Additionally, each patient sample must be transduced individually,
increasing time to use and costs substantially. Ideally, application of optical imaging would utilize a
universal imaging contrast reagent, which would permit universal imaging of all PDX.
In vivo near-infrared fluorescent (NIRF) optical imaging using exogenous fluorescent antibodies
targeting specific molecular markers has been applied to visualize tumor growth and therapeutic
interventions in multiple cancer models [23–25]. In the current study we mined for a marker that is
universally expressed in endometrial carcinoma, to serve as an imaging target for NIRF imaging of
orthotopic PDX models. Subsequently, epithelial cell adhesion molecule (EpCAM) was found to be
expressed in 98% of primary uterine patient samples and cell lines. Conjugation of EpCAM to the
near-infrared fluorophore Alexa680 yielded EpCAM-AF680, and its application as an optical imaging
contrast reagent was found to faithfully depict uterine tumors and metastases in both cell line derived
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and PDX mouse models. EpCAM-AF680 NIRF imaging was also successfully applied to monitor
orthotopic PDX in a therapeutic setting.
2. Results
2.1. Endometrial Carcinoma Cell Lines Express EpCAM In Vitro
In order to identify an optimal target for NIRF imaging of xenograft models, selected cell surface
proteins (EpCAM, activated leukocyte cell adhesion molecule (ALCAM), insulin-like growth factor
1 receptor alpha (IGF1R), and L1 cell adhesion molecule (L1CAM)) reported to be expressed in
endometrial carcinoma [26–33] were screened by flow cytometry in the endometrial carcinoma cell
line Ishikawa. EpCAM was found to have the highest expression, with positive staining in 99.9%
of cells and a mean fluorescent intensity (MFI) fold increase of 305.3 in comparison to unstained
cells (Figure 1A, Table S1). Further evaluation of the same panel in the endometrial carcinoma cell
lines AN3CA, Hec1B and RL95-2 (Figure 1B) was performed in order to verify that the high EpCAM
expression was not a unique feature of Ishikawa cells. Results demonstrated that all cell lines analyzed
presented with positive populations to all antigens in the following order; EpCAM (range: 48.5–99.9%),
ALCAM (range: 31.2–99.9%), L1CAM (range: 0.7–96.2%) and IGF1Rα (range: 2.5–66.7%) (Table S1).
Additionally, the average MFI of EpCAM (1.2 × 105 +/− 1.0 × 105 a.u.) across the four cell lines was
higher compared to ALCAM (4.6 × 104 +/− 1.8 × 104 a.u.), L1CAM (3.1 × 104 +/− 2.9 × 104 a.u.) and
IGF1Rα (1.4 × 104 +/− 5.8 × 103 a.u.) (Figure 1C). The average MFI fold increase in stained relative to
unstained cells was also higher for EpCAM (116.4 +/− 128.0) than for ALCAM (44.0 +/− 23.5), L1CAM
(23.2 +/− 19.0) and IGF1Rα (11.2 +/− 1.2) (Table S1). Overall, EpCAM was found to be the superior
target for antibody-based applications and was selected for further studies.
2.2. EpCAM is Highly Expressed in the Majority of Endometrial Carcinoma Primary Tumors
In order to confirm that EpCAM was not just aberrantly expressed on cell line cultures and was
in fact ubiquitously expressed in primary tumor tissues, we performed immunohistochemical (IHC)
analysis of EpCAM staining on a cohort of 153 endometrial carcinoma patients. In total, 98% (150/153)
of samples analyzed stained positive for EpCAM (Table S2). Of the positive patients, 80% (n = 123)
were classified as “EpCAM high”, and 20 % (n = 30) as “EpCAM low”. Only 2% (n = 3) of patients
did not stain for EpCAM. No significant association was found between EpCAM expression and age,
International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade, lymph node
metastasis or myometrial infiltration (Table S2). EpCAM was however significantly associated with
histologic type, and high EpCAM expression was observed in 84% of patients with endometrioid
endometrial carcinoma compared to 64% and 56% of patients with serous endometrial carcinoma and
carcinosarcomas, respectively (p = 0.002, Table S2). Although 36% of tumors with serous histology
were defined as “EpCAM low” according to our cut-off, they demonstrated consistent positive staining
(staining index (SI): 3–4 in all cases). No significant association between EpCAM expression and disease
specific survival was found in a univariate survival analysis (p = 0.49, Figure 1D). To confirm that
EpCAM expression is maintained following in vivo passage in immunodeficient mice we isolated cells
from a representative PDX model of endometrial carcinoma (PDX2) and performed flow cytometry
with an anti-EpCAM antibody. Positive expression of EpCAM was observed (Figure 1E). Together,
the data suggest that EpCAM can be targeted in both in vitro and in vivo applications.
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Figure 1. EpCAM is expressed in both endometrial carcinoma cell lines and tumors. Protein expression
of ALCAM, EpCAM, IGF-1Rα and L1CAM in Ishikawa (A) and AN3CA, Hec1B and RL95-2 (B) cell
lines demonstrated by flow cytometry using PE-conjugated antibodies. MFI values of EpCAM, ALCAM,
IGF-1Rα and L1CAM in the explored cell lines combined (C). Kaplan Meier plot illustrating the lack of
significant differences in disease specific survival between patients with high or low EpCAM expression
in primary tumor (D). In vitro protein expression of EpCAM in PDX-derived tumor cells (PDX 2)
demonstrated by flow cytometry (E). Abbreviations: Activated leukocyte cell adhesion molecule
(ALCAM), Epithelial cell adhesion molecule (EpCAM), Insulin-like growth factor 1 receptor alpha
(IGF1Rα), L1 cell adhesion molecule (L1CAM), Monoclonal antibody (mAb), Patient-derived xenograft
(PDX), and Phycoerythrin (PE).
2.3. EpCAM-AF680 Enables Early Imaging of Metastasis in Cell Line-Based Xenograft Models of
Endometrial Carcinoma
To validate that our EpCAM-AF680 conjugate was able to bind to endometrial carcinoma cells,
in vitro, NIRF imaging of luciferase-expressing (luc+) Ishikawaluc+ cells was performed. Cells were
imaged in parallel using BLI for comparison. Both modalities demonstrated similar increase in signal
Cancers 2020, 12, 370 5 of 18
with higher number of cells, and comparable r2 values (BLI: r2 = 0.88, EpCAM-AF680: r2 = 0.83,
Figure 2A,B). In vitro incubation with the EpCAM-AF680 antibody over 72 h did not significantly
affect proliferation or apoptosis in any of the cell lines examined (Figure 2C,D).
Figure 2. In vitro evaluation of EpCAM-AF680 as a NIRF imaging probe. In vitro imaging of
Ishikawaluc+ cells using BLI and EpCAM-AF680 NIRF demonstrates comparable photonic linearity (A)
and increase in signal (B) with higher number of cells (range: 0–106 cells). The lack of significant effects of
in vitro incubation with EpCAM-AF680 antibody on proliferation and apoptosis demonstrated by MTS
assay (C) and Annexin V/PI staining (D) in various cell lines. Abbreviations: Bioluminescent imaging
(BLI), Epithelial cell adhesion molecule (EpCAM), Near-infrared fluorescent (NIRF), and Propium
iodide (PI).
To validate EpCAM as an imaging biomarker prior to application in PDX models, we wanted to
confirm a correlation with NIRF and BLI, which is commonly used for preclinical imaging. Ishikawaluc+
cells with high EpCAM expression were therefore orthotopically implanted in mice (n = 4), and parallel
BLI and EpCAM-AF680 NIRF imaging performed every second week from week 6. Both modalities
were able to detect uterine tumors and disease progression from week 6 (Figure 3A). Interestingly,
suspected metastases were clearly evident using EpCAM-AF680 from week 6, which were not evident
in BLI until week 10 (Figure 3A). After necropsy, the intensity of signal in harvested organs was
evaluated by ex vivo BLI and EpCAM-AF680 NIRF imaging. Comparable ex vivo images were
generated from the two modalities, and presence of tumor cells in suspected sites of metastasis
confirmed by histological evaluation of HE-stained tissue (Figure 3B). Positive EpCAM staining was
demonstrated in both uterine tumors and metastases by IHC (Figure 3C).
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Figure 3. Optical imaging of tumor growth in an orthotopic Ishikawaluc+ xenograft model. In vivo BLI
and EpCAM-AF680 NIRF imaging of primary tumor growth in mice orthotopically implanted with
Ishikawaluc+ cells. Metastatic lesions (arrows) were detected at an earlier time point in EpCAM-AF680
NIRF images. A tumor free mouse was used as control (upper left) (A). Macroscopic images of
uterus, pancreas, lungs and abdominal metastases (B, upper panel) and corresponding ex vivo BLI and
EpCAM-AF680 NIRF images (B, middle panels). Tumor cells are demonstrated in H&E stained sections
(20x magnification) (B, lower panel). Positive EpCAM expression in primary tumor and metastases
is demonstrated by IHC (C). Abbreviations: Bioluminescent imaging (BLI), Epithelial cell adhesion
molecule (EpCAM), Hematoxylin and eosin (H&E), Immunohistochemistry (IHC), and Near-infrared
fluorescence (NIRF).
To validate that the correlation between EpCAM-AF680 NIRF imaging and BLI was not specific to
the Ishikawaluc+ model, an orthotopic xenograft model was also developed from the Hec1Bluc+ cell line
(n = 4) and imaged weekly. In this model, both EpCAM-AF680 NIRF and BLI demonstrated comparable
capacities in delineating primary tumors (Figure 4A). However, as observed with EpCAM-AF680
NIRF imaging of the Ishikawaluc+ model, distant metastatic lesions were already evident 6 weeks post
implantation with the NIRF approach although never detected with corresponding BLI (Figure 4A).
Ex vivo BLI and EpCAM-AF680 NIRF imaging correlated well across all infiltrated organs and were
confirmed by histology (Figure 4B, Figure S1). Positive EpCAM expression was demonstrated by IHC
Cancers 2020, 12, 370 7 of 18
in both primary tumor and metastatic lesions (Figure 4C). Additionally, we demonstrated a strong
correlation between BLI and EpCAM-AF680 NIRF (r = 0.77, Figure 4D).
Figure 4. Optical imaging of tumor growth in an orthotopic Hec1Bluc+ xenograft model. In vivo BLI
and EpCAM-AF680 NIRF imaging of primary tumor growth in mice orthotopically implanted with
Hec1Bluc+ cells. NIRF imaging enabled detection of metastatic lesions in the lung (arrows), which were
not evident on BLI in vivo (A). Macroscopic images of organs harvested during necropsy (B, upper
panel) and corresponding ex vivo BLI and EpCAM-AF680 NIRF images (B, middle panels). Tumor cells
are demonstrated in H&E stained sections (20x magnification) (B, lower panel). Positive EpCAM
expression in uterine tumor and metastases is demonstrated by IHC (C). Correlation plot of in vivo
NIRF and bioluminescent signal in all mice included in the cell line-based models (D). Abbreviations:
Bioluminescent imaging (BLI), Epithelial cell adhesion molecule (EpCAM), Hematoxylin and eosin
(H&E), Immunohistochemistry (IHC), and Near-infrared fluorescence (NIRF).
2.4. In Vivo EpCAM-AF680 NIRF Imaging Detects Uterine Tumors in PDX Models of Endometrial Carcinoma
Having demonstrated EpCAM-AF680 to be useful for preclinical imaging of cell line-based
orthotopic xenograft models of endometrial carcinoma, the goal was to apply this imaging strategy to
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monitor tumor development in PDX models. Primary tumor cells were harvested from endometrial
carcinoma patients during hysterectomy and used to generate orthotopic PDX models (Table S3).
In vivo EpCAM-AF680 NIRF imaging and fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT imaging
were performed in parallel to monitor tumor growth in four different PDX models (Figure 5A–D).
Variations in imaging time points of PDX1–4 are caused by different engraftment times for these four
models (range: 7–55 weeks). EpCAM-AF680 NIRF imaging enabled visualization of uterine tumors
in all four xenografts, demonstrating excellent contrast and strong fluorescent signal (Figure 5A–D).
Interestingly, PDX4 developed a uterine tumor that was clearly depicted on EpCAM-AF680 NIRF
images (Figure 5D), despite the primary tumor sample for that PDX exhibiting low expression of
EpCAM on IHC (SI: 4). PDX mice had suspected uterine tumors based on visual inspection of
reconstructed 18F-FDG PET/CT images (Figure 5A–D, Figure S2). However, in several of the scans
from PDX1–3, suspected lesions had standardized uptake values (SUV) below 2.5, which was the
threshold used to define tumors in PET images (Figure 5A–C, Figure S2). Overall, EpCAM-AF680 NIRF
imaging appeared to detect tumors at an earlier time point than 18F-FDG PET/CT. Uterine tumors were
also clearly discerned in EpCAM-AF680 NIRF images, whereas tumors in 18F-FDG PET/CT images
were more diffuse and difficult to distinguish from normal physiological tracer uptake in the intestine
(Figure 5A–D). Histological appearance and EpCAM expression were found to be similar in primary
tumor and corresponding xenograft in all cases (Figure 5E–H).
2.5. EpCAM-AF680 NIRF Imaging of Therapeutic Efficacy in An Orthotopic Endometrial Carcinoma
PDX Model
Having established that NIRF imaging with EpCAM-AF680 could be employed to non-invasively
monitor tumor growth in PDX models in a spatio-temporal manner, a cohort of mice (n = 24) were
orthotopically implanted with cells from a patient diagnosed with grade 3 endometrioid endometrial
carcinoma (PDX4) and treated with paclitaxel (n = 8), trastuzumab (n = 8) or vehicle control (n = 8).
Each mouse underwent EpCAM-AF680 NIRF imaging prior to initiation of therapy and post-treatment
(Figure 6A). Mice were also imaged once using 18F-FDG PET/CT (Figure 6B). Total fluorescence was
measured to evaluate the change in disease status over time (Figure 6C). Although not significant
(F(2,21) = 1.04, p = 0.37), there was a tendency toward lower NIRF signal in the paclitaxel (mean: 4.1 ×
106 +/− 2.0 × 106 PC) and trastuzumab (mean: 3.3 × 106 +/− 1.4 × 106 PC) treated groups compared
to controls (mean: 4.7 × 106 +/− 2.5 × 106 PC) post treatment (Figure 6C). While xenografts could be
clearly discerned in all mice using EpCAM-AF680 NIRF, for six mice no uterine tumor was identified
on 18F-FDG PET/CT (not shown). One mouse had missing PET data due to technical problems.
Mean standardized uptake values (SUVmean) of uterine tumors were estimated (group mean values:
control group; 3.3 +/− 0.4, paclitaxel group; 3.0 +/− 0.2, trastuzumab group; 3.0 +/− 0.3 mm3), but no
significant differences were observed between groups (F(2,14) = 1.37, p = 0.29, Figure 6D). Following
necropsy tumors were weighed. Consistent with findings from EpCAM-AF680 NIRF imaging there
were no statistically significant differences in tumor weights between groups (mean weight control
group; 1.06 +/− 0.73 g, paclitaxel group; 0.91 +/− 1.01 g, trastuzumab group; 1.01 +/− 0.77 g) (F(2,21) =
0.07, p = 0.93, Figure 6E). Histological examination of uterine tissue confirmed presence of tumor cells
in all samples (Figure 6F).
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Figure 5. In vivo imaging of tumor growth in PDX models using EpCAM-AF680 NIRF and 18F-FDG PET/CT. Longitudinal monitoring of uterine tumors of
different histologic types in PDX models using EpCAM-AF680 NIRF and 18F-FDG PET/CT imaging. Arrows mark probable uterine tumors in PET/CT images
(A–D). H&E staining demonstrating uterine tumor cells, and positive EpCAM IHC staining of uterine tumors from both donor patients and mouse xenografts
(20× magnification) (E–H). Large bladder removed from image for visualization purposes. An uncropped version of this image can be found in Figure S2.
Abbreviations: Epithelial cell adhesion molecule (EpCAM), Fluorine-18-fluorodeoxyglucose (18FDG), Hematoxylin and eosin (H&E), Near-infrared fluorescence
(NIRF), Patient-derived xenograft (PDX), Positron emission tomography/computed tomography (PET/CT), and Standardized uptake value (SUV).
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Figure 6. In vivo monitoring of paclitaxel or trastuzumab treatment in an endometrial carcinoma PDX model using EpCAM-AF680 NIRF imaging. EpCAM-AF680
NIRF images of mice treated with control vehicle (n = 8), paclitaxel (n = 8) or trastuzumab (n = 8) prior to (day 26) and after (day 55) treatment. Pre-and post-treatment
scans were paired and signal intensity scale synchronized for each individual mouse (A). Representative 18F-FDG PET/CT images (day 47), uterine tumors are
indicated by arrows (B). Group means of total fluorescent signal before (day 26) and after (day 55) treatment, n = 8 mice per group (C). Group means of total fluorescent
signal after treatment (day 55, n = 8 mice per group) compared to group SUVmean values measured in 18F-FDG PET/CT scans at day 47, control group: n = 6, paclitaxel
group: n = 5, trastuzumab: n = 6 (D). Tumor weights after necropsy on day 49 (control group: mouse 1, paclitaxel group: mouse 2), day 51(control group: mice 3 and 8,
trastuzumab group: mouse 2) or day 57 (all other mice), n = 8 in all groups (20×magnification) (E,F). Graphs are group means +/− SD. Abbreviations: Epithelial cell
adherence molecule (EpCAM), Fluorine-18-fluorodeoxyglucose (18F-FDG), Metabolic tumor volume (MTV), Near infrared fluorescence (NIRF), Positron emission
tomography/computed tomography (PET/CT), and Standardized uptake value (SUV).
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3. Discussion
Amongst the major challenges in endometrial carcinoma is the lack of treatment alternatives
targeting specific molecular alterations. PDX models are considered clinically relevant for studies
of targeted therapies, but monitoring of disease development, staging and treatment response is
challenging in an orthotopic setting. Non-invasive imaging modalities are auspicious tools to
overcome this problem as we have previously reported for BLI, MRI and PET/CT (with both 18F-FDG
and 18F-fluorothymidine as tracers) in cell line xenograft studies [18]. However, extension of these
modalities to the visualization of orthotopic PDX models required a more targeted approach. Previously,
NIRF imaging using EpCAM antibodies have been demonstrated to detect orthotopic tumors in cell
line-based xenograft models of head and neck, breast and colorectal cancer [24], as well as to visualize
metastatic lymph nodes [34] and improve detection of tumor margins [35] in preclinical prostate cancer
models. In the current study, we extend this approach to develop a comprehensive NIRF imaging probe
EpCAM-AF680 and demonstrate its feasibility in monitoring of orthotopic endometrial carcinoma
PDX models.
There are several benefits of using antibody-based NIRF imaging compared to other imaging
modalities. BLI is commonly used for preclinical imaging, but relies on genomic introduction of
reporter genes [36]. Optical imaging of EpCAM-AF680 is also directly applicable to new endometrial
carcinoma PDX models, whereas transfection of reporter genes must be repeated each time a new
model is generated. In the present study, we find that EpCAM-AF680 NIRF enables identification of
metastases. This is a major strength, as correct evaluation of disseminated disease is important for
both preclinical purposes as well as clinical management of disease [37]. Further, with NIRF imaging
there is no need for radioactive tracers. This sets fewer demands to facilities and staff, reduces costs
and makes NIRF imaging a more available modality for preclinical imaging. Additionally, application
of NIRF imaging adheres to the principle of the 3R’s as scan time is shorter compared to PET/CT
(refinement), and as the use of orthotopic PDX models yields clinically relevant information that may
limit the number of animals needed (reduction) [38].
To demonstrate the capacity of EpCAM-AF680 NIRF imaging to monitor tumor development
in a therapeutic setting, we imaged mice (PDX4) before and after treatment with paclitaxel or
trastuzumab. Paclitaxel is a part of the first-line adjuvant chemotherapeutic treatment of endometrial
carcinoma [39,40], while trastuzumab is an antibody targeting human epidermal growth factor 2
(HER2) that has been used for selected patients with endometrial carcinoma [41]. Patient 4 (from
whom PDX4 was generated) was treated with paclitaxel/carboplatin treatment but suffered disease
recurrence 8 months after primary surgery and later died from her disease. As the patient had positive
HER2 expression in tumor, we also wanted to treat PDX4 with trastuzumab to determine whether this
could improve the outcome. Unfortunately, no statistically significant effects of trastuzumab treatment
were detected, either by EpCAM-AF680 NIRF imaging or necropsy findings. Even though none of
these drugs were found to inhibit tumor development, the ability of EpCAM-AF680 NIRF imaging to
capture therapeutic response in vivo shows promise for use in future treatment studies in endometrial
carcinoma PDX models. However, as our results are based on treatment of a single PDX model, the
imaging method should be validated in multiple PDX models—preferably representing all subtypes of
the disease. It will also be important to validate the clinical relevance of new PDX models to ensure
that therapeutic response corresponds to that of their human donors. EpCAM-AF680 NIRF imaging
should also be used to monitor multiple treatment experiments with drugs exhibiting different degrees
of therapeutic response, in order to validate the clinical accuracy of the method as well as to establish a
cut-off for the lower detection limit.
Although NIRF is a powerful tool for imaging of cancer, there are some limitations. NIRF imaging
is not quantitative, and the lack of three-dimensional information makes it difficult to precisely identify
the exact anatomical location of tumors [36]. Some of these challenges may be overcome by linking
EpCAM-antibodies to radioactive isotopes and use them as PET tracers. This has been done with
the bispecific EpCAM/CD3ε binding antibody AMG 110, which has been linked to 89Zr and used to
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detect tumors in colorectal and head and neck cancer xenografts [42]. Combining the tumor-targeting
properties of EpCAM with three-dimensional PET/CT technology may create a translational imaging
tool that improves the value of both preclinical and diagnostic imaging of endometrial carcinoma.
EpCAM may also serve as an imaging target for image-guided surgery (IGS). Sentinel lymph
node removal is increasingly applied in endometrial carcinoma [43,44], but the fluorophore commonly
used for IGS (indocyanine green) is not tumor-specific [45,46]. Development of tumor-targeting probes
may improve the clinical utility. In our present study EpCAM-AF680 NIRF imaging allowed early
detection of metastases in endometrial carcinoma mouse models, indicating that EpCAM is expressed
in metastatic lesions. This, combined with the observed high proportion of endometrial tumors with
positive EpCAM staining in our cohort, suggests EpCAM as a potential biomarker for IGS that should
be further explored in future studies.
4. Materials and Methods
4.1. Monoclonal Antibodies for In Vitro Studies
To identify potential target molecules for NIRF imaging, databases (www.proteinatlas.org and
www.uniprot.org) were searched for proteins located on the surface of endometrial carcinoma cells.
Candidate proteins with reported overexpression in endometrial carcinoma compared to normal
epithelium (ALCAM, EpCAM and IGF1Rα) or with positive expression associated with aggressive
disease (L1CAM) were selected [26,28–33]. Direct PE-conjugated monoclonal antibodies (Mouse
Anti-EpCAM PE (clone EBA-1), PE Mouse Anti-Human CD221 (clone 1H7), PE Mouse Anti-Human
CD166 (clone 3A6) (all BD Biosciences, San Jose, CA, USA) and Mouse Anti-Human CD171 Antibody
(PE) (clone 03, Sino Biological Inc., Beijing, China) were purchased and tested by flow cytometry to
evaluate target expression in cell lines.
4.2. Cell Lines
The endometrial adenocarcinoma cell lines AN3CA, Hec1B, RL95–2 (all American Type Culture
Collection; Manassas, VA, USA), and Ishikawa (Sigma-Aldrich, St. Louis, MO, USA) were cultured in
a humidified atmosphere with 5% CO2, at 37 ◦C, under conditions as recommended by the suppliers.
All cell line growth mediums were supplemented with 2 mM L-glutamine and 100 IU/mL penicillin +
100 µg/mL streptomycin (all; Lonza, Basel, Switzerland).
4.3. Flow Cytometry
In total, 0.5 × 106 cells (cell lines) or 0.2 × 106 cells (patient cells) per sample were washed twice
and resuspended in 50 µL wash buffer (1% bovine serum albumin (BSA)/phosphate buffered saline
(PBS)). Samples were protected from light while incubated for 30 min on ice with PE-conjugated
antibodies. After incubation cells were washed twice with 1% BSA/PBS and resuspended in 150 µL
PBS. Samples were analyzed using an Accuri™ C6 (BD Biosciences, San Jose, CA, USA) flow cytometry
system, and data processed using CFlow Sampler Analysis 1.0.227.4 software.
4.4. Validation of EpCAM as Relevant Marker for Endometrial Carcinoma
A cohort of 153 endometrial carcinoma patients representative of the Bergen Gynecologic Biobank
was selected, and used for evaluation of EpCAM protein expression. Clinical and histopathological
information was retrieved from medical records. Formalin fixed paraffin embedded tissue from
primary endometrial carcinomas was used to generate tissue microarrays as previously described [47].
IHC staining was performed according to a standardized institutional protocol [18]. EpCAM was
detected using a monoclonal antibody (D9S3P; Cell Signaling Technologies, Danvers, MA, USA [48])
under the following conditions: pH 6, 1:200 dilution, incubated for 60 min at room temperature. SI was
calculated for each patient as previously described [47]. Briefly, slides are given one score of 0–3
based on staining intensity (0 = no staining, 3 = strong staining) and one score of 0–3 based on the
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area of the tumor with positive staining (0 = no staining, 1 = less than 10%, 2 = 10%–50%, 3 = >50%).
The two scores are then multiplied, giving a final SI within the range of 0–9. Both cytoplasmic and
membranous staining of EpCAM was observed in tumor cells, and overall staining was evaluated
without considering sub-cellular localization. “EpCAM high” was defined as SI: 6–9, while “EpCAM
low” was defined as SI: 0–4.
4.5. Alexa Fluor 680 (AF680) Conjugation of EpCAM Antibody
A monoclonal mouse anti-human low endotoxin anti-EpCAM antibody (MCA1870EL, clone
VU-1D9; BioRad, Hercules, CA, USA) was purchased for in vivo experiments. Anti-EpCAM antibody
was conjugated to AF680 using the SAIVI Rapid Antibodies Labeling Kit (Invitrogen/Thermo Fisher
Scientific Inc., Waltham, MA, USA) following instructions from the manufacturer. A Nanodrop
1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA) was used to determine protein
concentration and degree of labeling. To confirm fluorescent signal, series of cells (0, 104, 105 and 106)
were seeded in 96-well plates as 100 µL cell suspensions and incubated with 0.4 µg EpCAM-AF680 for
60 min on ice while protected from light. Excess antibody was removed by washing with 1% BSA/PBS.
In vitro NIRF imaging and data analyses were performed using the IVIS Spectrum In Vivo Imaging
System (PerkinElmer, Waltham, MA, USA).
4.6. Cell Transfection, Viability and Proliferation Assays
Ishikawa and Hec1B cells were stably transfected with a luciferase-expressing construct by
retroviral infection, as previously described [18]. Luc+ cells (Hec1Bluc+, Ishikawaluc+) were selected
using 1 µg/mL puromycin (Sigma-Aldrich, St. Louis, MO, USA). Luciferase activity was confirmed by
seeding series of cells (0, 104, 105, and 106) in 96-well plates as 100 µL cell suspensions, and performing
in vitro BLI 10 min after addition of d-luciferin (2.5 mg/mL; Promega, Madison, WI, USA) using the
IVIS Spectrum In Vivo Imaging System (PerkinElmer, Waltham, MA, USA).
Proliferation was assessed using the CellTiter 96®AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI, USA) as described by the supplier. AN3CA, Hec1Bluc+, Ishikawaluc+, and
RL95–2 cells were seeded in 96-well plates and incubated with EpCAM-AF680 antibody. Absorbance
(490 nm) was recorded one hour after adding 20 µL of substrate, using a TECAN Magellan Sunrise
plate reader and TECAN Magellan software version 6.3 (both Tecan, Männedorf, Switzerland).
All experiments were performed in triplicates.
Evaluation of apoptosis was performed by Annexin V/propium iodine (PI) staining. Cells were
incubated with EpCAM-antibody (MCA1870EL), harvested, washed twice in PBS, and suspended in
1x binding buffer (Thermo Fisher Scientific, Waltham, MA, USA). APC Annexin V and PI (both Thermo
Fisher Scientific, Waltham, MA, USA) were applied for 15 min at room temperature protected from
light, and samples immediately analyzed by flow cytometry.
4.7. Orthotopic Mouse Models
Female NOD/SCID IL2rγnull (NSG) mice were bred at the University of Bergen animal facilities or
purchased from Charles River Laboratories (Saint-Germain-Nuelles, France), and kept in individually
ventilated cages with a maximum of 5 mice in each cage. Ad libitum access to food and water was
provided. Mice were fed with low-autofluorescence rodent imaging diet (2018S Teklad Global 18%
Protein Rodent Diet, Envigo, Cambridgeshire, UK, or D10001, Research Diets Inc., New Brunswick,
NJ, USA) for at least two weeks prior to imaging. Endometrial carcinoma cells were implanted
orthotopically in the left uterine horn as previously reported [18]. Mice were monitored for lethargy,
ataxia and abdominal enlargement, and were sacrificed by cervical dislocation following any of these
symptoms or weight loss of ≥10%.
Cell line-based orthotopic models were generated by uterine implantation of 1 × 106 Hec1Bluc+
(n = 4) or Ishikawaluc+ (n = 4) cells. Parallel BLI and EpCAM-AF680 NIRF imaging were performed
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either weekly (Hec1Bluc+) or every other week (Ishikawaluc+), starting 6 weeks after implantation.
Ex vivo imaging of organs was carried out immediately after euthanasia.
Biopsies from human primary tumors were collected during hysterectomy and kept on ice until
processing. Tumor tissue was prepared by manual dissociation as previously described [18], and cells
were suspended in matrigel prior to orthotopic implantation in mice (P0-generation). When mice were
in a moribund state, PDX models were maintained by re-implantation in new mice (P1-generation, etc.).
In total, PDX models generated from 4 patients have been included in this study. Tumor growth in PDX
mice was monitored in parallel using EpCAM-AF680 NIRF- and dynamic 18F-FDG PET/CT imaging.
4.8. EpCAM-AF680 NIRF Imaging for Monitoring of Therapeutic Effect in An Endometrial Carcinoma
PDX Model
Primary human tumor cells (PDX4) were isolated from hysterectomy specimen, expanded in
short-time culture and orthotopically implanted in 24 mice (1 × 106 cells per mouse). Then, 28 days
after implantation, animals were randomized into three treatment groups (n = 8 mice per group).
Baseline NIRF signal, body weight and time of implantation were evaluated by ANOVA-testing
to ensure that there were no significant differences between groups prior to starting treatment.
Mice were treated with 10 mg/kg trastuzumab i.p. once weekly [49] or 12 mg/kg paclitaxel i.p. twice
weekly [50]. The control group received equivalent volumes of saline twice weekly. As trastuzumab
was administered only once weekly, mice in the trastuzumab group were injected with saline once
a week in order to receive the same number of injections as mice in the other treatment groups.
EpCAM-AF680 NIRF imaging was performed prior to starting treatment (day 26) and after treatment
(day 55). 18F-FDG PET/CT imaging was performed on day 47. Mice were fasted 12 h prior to PET/CT
imaging to reduce tracer uptake in the gut. Animals were sacrificed when developing signs of clinical
disease, or at day 57 (final endpoint). After necropsy, tumors were weighed, and tissue samples
collected for histological evaluation. The main events of the treatment study are presented in Figure S3.
4.9. In Vivo BLI
Mice implanted with Luc+ cells were injected with 150 mg/kg d-luciferin (Promega, Madison,
WI, USA) i.p. 10 min prior to imaging. Animals were anesthetized using 3% isoflurane (IsoFlo vet.
Zoetis, Parsippany, NJ, USA), + 1 L/min O2 for induction, and maintained with 1.5–2% isoflurane +
1.0 L/min O2 for imaging. Bioluminescent images were obtained using an Optix MX3 Time-Domain
Optical Imager (ART Inc., Saint-Laurent, QC, Canada) with raster scan points 1.5 mm apart. Images
were analyzed using the Optix OptiView software (version 2.02; ART Inc., Saint-Laurent, QC, Canada).
A region of interest (ROI) was manually drawn around the abdomen and thorax to measure total
bioluminescent signal in in vivo scans. For ex vivo images, ROIs were manually drawn around
each organ.
4.10. In Vivo NIRF
Then, 24 h prior to imaging, animals were injected with the EpCAM-AF680 antibody in the tail
vein (cell line models: 50 µg/mouse, PDX1–3: 75 µg/mouse, and PDX4 + treatment study: 60 µg/mouse).
Animals were depilated before imaging, and urine was manually removed to avoid excess fluorescent
signal from the bladder. EpCAM-AF680 NIRF images were obtained using the Optix MX3 Time-Domain
Optical Imager (ART Inc., Saint-Laurent, QC, Canada), λex = 670 nm, λem = 700 LP, raster scan points
1.5 mm apart. Image analysis was performed using the Optix OptiView software (version 2.02; ART
Inc., Saint-Laurent, QC, Canada). A tumor free mouse injected with EpCAM-AF680 was imaged in
parallel as control. In cell line models a ROI was manually drawn around the abdomen and thorax
to measure total fluorescent signal of in vivo scans. For ex vivo images, ROIs were manually drawn
around each organ. In the PDX treatment study, background signal was removed prior to measuring
the fluorescent signal. For visualization of tumor progression, pre- and post-treatment images were
paired, and the signal intensity scale was synchronized for each mouse.
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4.11. F-FDG PET/CT Acquisition and Image Analysis
Integrated PET/CT whole-body images were collected using a nanoScan PET/CT (Mediso Medical
Imaging Systems Ltd, Budapest, Hungary), with spatial resolution 800 µm (PET) and 30 µm (CT)
as previously described [18]. Animals were anesthetized with 3% sevoflurane (SevoFlo vet., Zoetis,
Parsippany, NJ, USA) during tracer injection and imaging. A CT uptake (50 kVp, 0.1 mAs) was
performed for attenuation correction and anatomical localization of the PET signal. 18F-FDG was
injected i.v. in the tail vein at start of the 1 h PET acquisition, and static attenuation corrected PET images
with voxel size of 0.4 mm3 were reconstructed summing the last 30 min of the scan. PET/CT images
were reviewed for tumor uptake and/or other pathologically suspicious areas. Measurements of
SUVmean included voxels with SUV above 2.5, as previously reported for endometrial carcinoma
patients [51].
4.12. Statistical Analyses
SPSS Statistics software (version 24.0; IBM Corp., Armonk, NY, USA) was used for statistical
analyses. All statistical tests were two-sided, and p-values ≤ 0.05 were regarded statistically significant.
Disease-specific survival curves were generated using the Kaplan–Meier method, and survival between
groups compared using the log rank (Mantel–Cox) test. In the patient series time of surgery was
used as entry date, and time to death due to endometrial carcinoma was defined as endpoint.
Categorical variables were evaluated using the Pearson Chi-square test. Linear correlation between
continuous variables was evaluated by calculating the Pearson correlation coefficient. One-way
analysis of variance was performed to compare group means in the PDX treatment study.
4.13. Approvals
All animal experiments were approved by the Norwegian State Commission for Laboratory
Animals (FOTS ID 6735) and have been conducted according to the European Convention for the
Protection of Vertebrates Used for Scientific Purposes. Ethical approval for inclusion of patients
has been granted by the Western Regional Committee for Medical and Health Research Ethics (REK
2009/2315, REK 2014/1907, REK 2018/594). Written informed consent was obtained from all participating
patients prior to inclusion in the Bergen Gynecologic Biobank.
5. Conclusions
EpCAM-AF680 NIRF imaging enables evaluation of treatment response in clinically relevant
endometrial carcinoma PDX models and may facilitate translational studies of new targeted treatments
and corresponding response predicting markers. EpCAM may serve as a translational imaging
biomarker and is a potential target for IGS.
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